Joseph A Ludwig, MD
Department of Sarcoma Medical Oncology, Division of Cancer Medicine
About Dr. Joseph A Ludwig
Dr. Joseph Ludwig is a physician-scientist who specializes in the study and care of Ewing’s and other bone and soft-tissue sarcomas. He received his medical degree from the University of Iowa, completed residency and research fellowship at Mayo Clinic, and medical oncology fellowship at the National Institutes of Health. Ludwig has been a member of the MD Anderson faculty since 2006. His research program, which encompasses both basic and translational endpoints, seeks to understand how the tumor microenvironment regulates the spatial organization, phenotype, and differentiation state of cancer. Ludwig’s major focus is determine how these parameters impact the sensitivity of bone and soft-tissue sarcomas to targeted therapy in an effort to improve response rates in these patients.
Present Title & Affiliation
Primary Appointment
Professor, The University of Texas MD Anderson Cancer Center, Houston
Adjunct Professor, Rice University, Houston, TX
Dual/Joint/Adjunct Appointment
Professor, The University of Texas MD Anderson Cancer Center, Houston
Adjunct Professor, Rice University, Houston, TX
Clinical Interests
Dr. Ludwig is an international expert in the treatment of Ewing sarcoma, osteosarcoma, and DSRCT.
Education & Training
Degree-Granting Education
| 1998 | University of Iowa College of Medicine, Iowa City, Iowa, US, Medicine, MD |
| 1994 | University of Iowa College of Business, Iowa City, Iowa, US, Business Administration, BBA |
Postgraduate Training
| 2002-2006 | Clinical Research Fellowship, Medical Oncology, National Cancer Institute, Bethesda, Maryland |
| 2001-2002 | Research Fellowship, Molecular Therapeutics, Mayo Graduate School of Medicine, Jacksonville, Florida |
| 1998-2001 | Clinical Residency, Internal Medicine, Mayo Graduate School of Medicine, Jacksonville, Florida |
Licenses & Certifications
| 2006 | Texas Medical License |
| 2005 | American Board of Internal Medicine-Medical Oncology |
| 2001 | American Board of Internal Medicine |
Experience & Service
Faculty Academic Appointments
Associate Professor, Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2014 - 2023
Assistant Professor, Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 2006 - 2014
Other Professional Positions
Hospitalist, St. Vincent's Medical Center, Jacksonville, FL, 2001 - 2002
Intramural Institutional Committee Activities
Committee member, Institutional Review Board (IRB), The University of Texas MD Anderson Cancer Center, 2020 - Present
Committee member, Data Safety Monitoring Committee (DSMC), MD Anderson Cancer Center, 2020 - Present
Extramural Institutional Committee Activities
Member, Osteosarcoma/Ewing Sarcoma Working Group, The University of Texas MD Anderson Cancer Center, 2014 - Present
Member, Clinical Research Committee, The University of Texas MD Anderson Cancer Center, 2009 - 2011
Editorial Activities
Editor, Bone Oncology, 2018 - Present
Editor, Sarcoma, 2012 - Present
Honors & Awards
| 2006 | Federal Technology Transfer Award |
| 2005 | American Society of Clinical Oncology (ASCO) Young Investigator Award, American Society Clinical Oncology |
| 2005 | NIH Fellows Award in Research Excellence, National Institute of Health |
| 2001 | Award Winner in ACP poster competition, American College of Physicians-American Society of Internal Medicine, Florida Chapter |
| 2001 | Mayo Graduate School of Medicine Resident Research Award, Mayo Graduate School of Medicine |
| 1995 | Medical Student Research Fellowship, University of Iowa College of Medicine |
| 1994 | Honors Research Practicum, University of Iowa |
| 1990 | National Dean's List, University of Iowa |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2020. Sarcoma Seminar Series. Conference. MD Anderson Cancer Center. Houston, TX, US.
National Presentations
- 2020. A Phase 1/2 Study of TK-216, a novel Anti-ETS Agent for Ewing sarcoma. Conference. ESMO, US.
- 2020. A Phase 1/2 Study of TK-216, a novel Anti-ETS Agent for Ewing sarcoma. Conference. CTOS, US.
- 2019. Advances in Tissues Engineering. Conference. Rice University. Houston, TX, US.
- 2014. Drug Sensitivity of Ewing's Sarcoma cells in Biomimetic Substrate. Invited. NCI Working Group Conference: Biomimetic Tissue Engineered Systems for Advancing Cancer Research. Washington, D.C, WA, US.
- 2007. Phase II Trial of Perifosine in Patients with Chemo-Insensitive Sarcoma. Conference. 13th Annual CTOS Meeting. Seattle, WA, US.
- 2005. Pgp-mediated sensitivity to thiosemicarbazones for treatment of drug resistance cancers. Invited. NIH. Bethesda, MD, US.
- Selective Toxicity of Thiosemicarbazone Derivatives for MDR1-positive cells as a New Strategy to Circumvent Multidrug Resistance in Cancer. Invited. 2nd Annual ABC-transporter Meeting. Frederick, MD, US.
Formal Peers
- 2016. Emerging Targeted Therapies for Ewing Sarcoma. Invited, IL.
- 2008. The role of tissue engineered tumors for evaluation of novel drug candidates for treatment of cancer. Invited. Houston, TX, US.
- NIH Fellows Lecture. Visiting. Bethesda, MD, US.
Grant & Contract Support
| Date: | 2027 - 2020 |
| Title: | Understanding how the Desmoplastic Stroma Niche Supports Desmoplastic Small Round Cell Tumors |
| Funding Source: | FP00030838 |
| Role: | Co-I |
| ID: | 14669889 - FP00030838 |
| Date: | 2026 - 2028 |
| Title: | Defining RBM39-Dependent Splicing as a Therapeutic Vulnerability in Ewing Sarcoma |
| Funding Source: | The Andrew McDonough B+ Foundation |
| Role: | PI |
| ID: | PRTMPL172014 |
| Date: | 2025 - 2030 |
| Title: | MDACC-Rice T32 Application |
| Funding Source: | NIH/NCI |
| Role: | Co-I |
| ID: | PA-25-168, Ruth L. Kirschstein NRSA Institutional Research Training Grant T32 |
| Date: | 2025 - 2029 |
| Title: | An innovative platform trial to target oncogenic pathways in Ewing sarcoma |
| Funding Source: | CPRIT |
| Role: | PI |
| ID: | FP00026195_iiract2_rfa - Resubmission |
| Date: | 2025 - 2028 |
| Title: | Developing a clinically effective multiparametric MRI model to differentiate imaging signatures of treatment-naïve osteosarcoma subtypes and evaluate treatment response |
| Funding Source: | CPRIT |
| Role: | Co-I |
| ID: | RP260200 - R-26.1-IIRACSBC- Individual Investigator Research Awards for Computational Systems Biology of Cancer |
| Date: | 2025 - 2030 |
| Title: | Dual Targeting of EWS-FLI1 and STAT3 to Suppress Metastasis and Reprogram the Tumor Immune Environment |
| Funding Source: | City of Hope Comprehensive Cancer Center - V Foundation for Cancer Research |
| Role: | PI |
| ID: | City of Hope Comprehensive Cancer Center - V Foundation for Cancer Research |
| Date: | 2025 - 2028 |
| Title: | Closing the Gap: A Pharma/Academic partnership to conduct preclinical & phase 0 IND-enabling studies of innovative agents against validated ES targets |
| Funding Source: | St. Baldrick’s Foundation |
| Role: | PI |
| ID: | FP00026106_Advancing Cures for Ewing Sarcoma (ACES) |
| Date: | 2025 - 2029 |
| Title: | RAPID Seamless Phase 2/3 Platform Trial for Orphan Pediatric Sarcoma |
| Funding Source: | US FDA |
| Role: | PI |
| ID: | FP00024483 |
| Date: | 2024 - 2028 |
| Title: | An innovative platform trial to co-target the IGF/PI3K/mTOR pathway in |
| Funding Source: | CPRIT |
| Role: | PI |
| ID: | FP00023214 |
| Date: | 2024 - 2031 |
| Title: | Preclinical evaluation of a LX-101 – alone and in combination with inhibitors against PI3K and mTOR – to co-target the IGF-1/PI3K/mTOR pathway in Ewing sarcoma & DSRCT |
| Funding Source: | Lirum Therapeutics |
| Role: | PI |
| ID: | FP/RCTS ID: 00063642_AWD00008618_RCTS# 63642 |
| Date: | 2024 - 2029 |
| Title: | Deciphering Fusion Protein Oncogenesis in DSRCT, CIC::DUX4, and BCOR::CCNB3 associated Sarcomas |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | TFCC U01 - Ludwig |
| Date: | 2023 - 2026 |
| Title: | Building a centralized resource for DSRCT: Patient registry with genomic data, database of immuno- and radioimmunotherapy targets, and list of research models |
| Funding Source: | MSKCC |
| Role: | Co-I |
| Date: | 2023 - 2025 |
| Title: | Neuroendocrine Reprogramming in DSRCT Resistance Mechanisms and Treatment Strategies |
| Funding Source: | DOD CDMRP |
| Role: | PI |
| ID: | RA220160 |
| Date: | 2023 - 2025 |
| Title: | Ewing sarcoma microdevice project |
| Funding Source: | Gaylord Foundation |
| Role: | PI |
| ID: | FP00020067 |
| Date: | 2023 - 2028 |
| Title: | The epigenetic impact and therapeutic opportunity of AR-directed therapy for DSRCT |
| Funding Source: | CPRIT |
| Role: | Co-PI |
| ID: | RP240272 |
| Date: | 2022 - 2023 |
| Title: | Ewing sarcoma gene dependencies that regulate cell fate / differentiation |
| Funding Source: | St. Baldrick's Foundation |
| Role: | PI |
| Date: | 2022 - 2027 |
| Title: | Deciphering how the AXL-YAP/TAZ feedback loop, other gene regulatory networks, and biophysical cues regulate osteosarcoma cell fate and metastasis |
| Funding Source: | NIH/NCI |
| Role: | Multiple PI |
| Date: | 2022 - 2022 |
| Title: | IK-930 mediated inhibition of the oncogenic TAZ-CAMT1 fusion protein in Epithelioid Hemangioendothelioma (EHE) |
| Funding Source: | Ikena Oncology |
| Role: | PI |
| Date: | 2022 - 2026 |
| Title: | RAPID Rx—DSRCT: The Rapid Advancement of Promising Innovative Drugs (RAPID) for DSRCT |
| Funding Source: | Alex's Lemonade Stand |
| Role: | Multiple PI |
| Date: | 2021 - 2023 |
| Title: | Preclinical evaluation of the xentuzumab/temsirolimus backbone in Ewing sarcoma in combination with IGF-1R or PI3K inhibitors |
| Funding Source: | Boehringer Ingelheim |
| Role: | PI |
| Date: | 2021 - 2026 |
| Title: | Deciphering the gene regulatory networks and biophysical cues that sustain high-grade osteosarcoma |
| Funding Source: | NIH/NCI |
| Role: | Co-PI |
| ID: | 1 R01 CA255518-01A1 |
| Date: | 2021 - 2026 |
| Title: | Targeting EMT-TFs and TME to block drug-induced lineage plasticity in osteosarcoma |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 CA258044 |
| Date: | 2018 - 2025 |
| Title: | A Phase 1, Dose Escalation Study of Intravenous TK216 in Patients with Relapsed or Refractory Ewing Sarcoma |
| Funding Source: | Oncternal |
| Role: | Co-PI |
| Date: | 2018 - 2019 |
| Title: | Biophysical force regulates YAP/TAZ in Ewing sarcoma to control cell fate |
| Funding Source: | St. Baldrick's Foundation |
| Role: | PI |
| ID: | Unknown |
| Date: | 2017 - 2023 |
| Title: | Microdevice Enabled Drug Micro-dosing in Ewing sarcoma |
| Funding Source: | Gaylord Foundation |
| Role: | PI |
| Date: | 2017 - 2023 |
| Title: | YAP/TAZ-mediated Effects upon Dedifferentiated Liposarcoma |
| Funding Source: | Moeller Foundation |
| Role: | Co-I |
| Date: | 2015 - 2018 |
| Title: | Preclinical investigation of OMTX503 for Ewing sarcoma |
| Funding Source: | Oncomatryx |
| Role: | PI |
| Date: | 2015 - 2023 |
| Title: | Desmoplastic Small Round Cell Sarcoma (DSRCT) |
| Funding Source: | Monzingo Foundation |
| Role: | PI |
| Date: | 2015 - 2016 |
| Title: | Biologically Targeted Therapy for DSRCT |
| Funding Source: | Young Texans Against Cancer |
| Role: | PI |
| Date: | 2014 - 2020 |
| Title: | 3D Model of Human Ewing Sarcoma |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | R01 CA180279-A101 |
| Date: | 2007 - 2009 |
| Title: | Personalize Therapy for Drug-Resistant Osteosarcoma |
| Funding Source: | NIH/NCI |
| Role: | PI |
| ID: | L30 CA130659-01 |
| Date: | 2005 - 2006 |
| Title: | ASCO Young Investigator Award |
| Funding Source: | American Society of Clinical Oncology (ASCO) |
| Role: | PI |
| ID: | unknown |
Selected Publications
Peer-Reviewed Articles
- Beird, H, Ho, C, Cardenas Zuniga, R, Ahmed, A, Agyemang, C, Truong, D, Murgas, KA, Stephan, C, Park, YS, Powell, RT, Tym, JE, Landers, S, Schmidt, S, Osman, NM, Araujo, DM, Conley, AP, Somaiah, N, Al-Lazikani, B, Ludwig, JA, Futreal, A. Drug Screening of Sarcoma Cells. Cancer Research Communications 6(6):1425-1434, 2026. e-Pub 2026. PMID: 42165630.
- Denu RA, Kochat V, Zheng Z, Satpati S, Truong DD, Arslan E, Weistuch C, Divenko M, Wu M, Padron W, Ingram DR, Wani KM, Wang WL, Landers SM, Beird HC, McCuisto JL, Simmons A, Albertorio-Saez LM, Maryanski DN, Szany CC, Venters BJ, Windham CL, Keogh MC, Torres KE, Roland CL, Keung EZ, Haddad EFN, Lazar AJ, Ludwig JA, Somaiah N, Rai K. Spatially-resolved single cell atlas of liposarcoma reveals lineage hierarchies, immune niches, and regulatory circuits. bioRxiv, 2026. e-Pub 2026. PMID: 41929055.
- Jin Y, Jia Z, Xia X, Gordon NB, Ludwig JA, Somaiah N, Li S. Anti-CD137 agonist antibody-independent and clinically feasible preparation of tumor-infiltrating lymphocytes from soft tissue sarcoma and osteosarcoma. Front Immunol 16:1557006, 2025. e-Pub 2025. PMID: 40145091.
- Patel, R, Bishop, AJ, Lazar, A, Lin, PP, Benjamin, RS, Patel, S, Ludwig, JA, Ravi, V, Vaporciyan, AA, Araujo, DM. Primary Intrathoracic Synovial Sarcoma. Cancers 17(5), 2025. e-Pub 2025. PMID: 40075593.
- Patel, R, Delclos, GL, Desantis, SM, Cannell, MB, Lupo, PJ, Bishop, AJ, Lazar, A, Lin, PP, Benjamin, RS, Patel, S, Ludwig, JA, Ravi, V, Livingston, JA, Somaiah, N, Alejandra Zarzour, M, Conley, AP, Araujo, DM. Does the Primary Tumor Site Drive Biology for Patients With Synovial Sarcoma?. American Journal of Clinical Oncology: Cancer Clinical Trials 48(1):21-27, 2025. e-Pub 2025. PMID: 39224003.
- Patel, R, Feit, J, Werling, G, White, NM, Bishop, AJ, Lin, PP, Valenzuela Perez, RF, Lazar, A, Benjamin, RS, Patel, S, Ludwig, JA, Ravi, V, Livingston, JA, Zarzour, MA, Conley, AP, Somaiah, N, Araujo, DM. Primary Synovial Sarcoma of the Abdomen and Pelvis. American Journal of Clinical Oncology: Cancer Clinical Trials Publish Ahead of Print, 2025. e-Pub 2025. PMID: 41342607.
- Ludwig JA. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma (ARMS) patients on first-line systemic therapies: a single-institution cohort. Rare Tumors, 2024. e-Pub 2024. PMID: 39105190.
- Meyers PA, Federman N, Daw N, Anderson PM, Davis LE, Kim A, Macy ME, Pietrofeso A, Ratan R, Riedel RF, Trucco M, Breitmeyer JB, Toretsky JA, Ludwig JA. Open-Label, Multicenter, Phase I/II, First-in-Human Trial of TK216: A First-Generation EWS::FLI1 Fusion Protein Antagonist in Ewing Sarcoma. J Clin Oncol:JCO2400020, 2024. e-Pub 2024. PMID: 38954782.
- Truong DD, Weistuch C, Murgas KA, Admane P, King BL, Chauviere Lee J, Lamhamedi-Cherradi SE, Swaminathan J, Daw NC, Gordon N, Gopalakrishnan V, Gorlick RG, Somaiah N, Deasy JO, Mikos AG, Tannenbaum A, Ludwig J. Mapping the Single-cell Differentiation Landscape of Osteosarcoma. Clin Cancer Res, 2024. e-Pub 2024. PMID: 38775859.
- Magrath JW, Goldberg IN, Truong DD, Hartono AB, Sampath SS, Sampath SS, Jackson CE, Jackson CE, Ghosh A, Ghosh A, Cardin DL, Cardin DL, Zhang H, Zhang H, Ludwig JA, Ludwig JA, Lee SB, Lee SB. Enzalutamide induces cytotoxicity in desmoplastic small round cell tumor independent of the androgen receptor. Commun Biol 7(1):411, 2024. e-Pub 2024. PMID: 38575753.
- Thirasastr P, Sutton TL, Joseph CP, Lin H, Amini B, Mayo SC, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Nassif Haddad EF, Nakazawa MS, Zhou X, Heinrich MC, Somaiah N. Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?. Cancers (Basel) 16(5), 2024. e-Pub 2024. PMID: 38473266.
- Nakazawa, MS, Livingston, JA, Zarzour, MA, Bishop, AJ, Ratan, R, Ludwig, JA, Araujo, DM, Somaiah, N, Ravi, V, Nassif, EF, Roland, CL, Lazar, A, Guadagnolo, BA, Harrison, DJ, Benjamin, RS, Patel, S, Conley, AP. Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies. Rare Tumors 16, 2024. e-Pub 2024. PMID: 39105190.
- Truong, D, Weistuch, C, Murgas, KA, Deasy, JO, Mikos, AG, Tannenbaum, A, Ludwig, JA. Mapping the Single-cell Differentiation Landscape of Osteosarcoma. bioRxiv : the preprint server for biology, 2023. e-Pub 2023. PMID: 37745374.
- Truong DD, Lamhamedi-Cherradi SE, Porter RW, Krishnan S, Swaminathan J, Gibson A, Lazar AJ, Livingston JA, Gopalakrishnan V, Gordon N, Daw NC, Navin NE, Gorlick R, Ludwig JA. Dissociation protocols used for sarcoma tissues bias the transcriptome observed in single-cell and single-nucleus RNA sequencing. BMC Cancer 23(1):488, 2023. e-Pub 2023. PMID: 37254069.
- Carmagnani Pestana R, Moyers JT, Roszik J, Sen S, Hong DS, Naing A, Herzog CE, Fu S, Piha-Paul SA, Rodon J, Yap TA, Karp DD, Tsimberidou AM, Pant S, Zarzour MA, Ratan R, Ravi V, Benjamin RS, Lazar AJ, Wang WL, Daw N, Gill JB, Harrison DJ, Lewis VO, Roland CL, Patel SR, Livingston JA, Somaiah N, Ludwig JA, Conley AP, Hamerschlak N, Gorlick R, Meric-Bernstam F, Subbiah V. Impact of Biomarker-Matched Therapies on Outcomes in Patients with Sarcoma Enrolled in Early-Phase Clinical Trials (SAMBA 101). Clin Cancer Res 29(9):OF1-OF11, 2023. e-Pub 2023. PMID: 37058010.
- Thirasastr P, Lin H, Amini B, Wang WL, Cloutier JM, Nassif EF, Keung EZ, Roland CL, Feig B, Araujo D, Benjamin RS, Conley AP, Livingston JA, Ludwig J, Patel S, Ratan R, Ravi V, Zarzour MA, Zhou X, Somaiah N. Retrospective evaluation of the role of gemcitabine-docetaxel in well-differentiated and dedifferentiated liposarcoma. Cancer Med 12(4):4282-4293, 2023. e-Pub 2023. PMID: 36151848.
- Moyers JT, Pestana RC, Roszik J, Hong DS, Naing A, Fu S, Piha-Paul S, Yap TA, Karp D, Rodon J, Livingston A, Zarzour MA, Ravi V, Patel S, Benjamin RS, Ludwig J, Herzog C, Ratan R, Somaiah N, Conley A, Gorlick R, Meric-Bernstam F, Subbiah V. Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102). Clin Cancer Res 29(2):401-409, 2023. e-Pub 2023. PMID: 36288393.
- Nassif EF, Cope B, Traweek R, Witt RG, Erstad DJ, Scally CP, Thirasastr P, Zarzour MA, Ludwig J, Benjamin R, Bishop AJ, Guadagnolo BA, Ingram D, Wani K, Wang WL, Lazar AJ, Torres KE, Hunt KK, Feig BW, Roland CL, Somaiah N, Keung EZ. Real-world use of palbociclib monotherapy in retroperitoneal liposarcomas at a large volume sarcoma center. Int J Cancer 150(12):2012-2024, 2022. e-Pub 2022. PMID: 35128664.
- Lamhamedi-Cherradi SE, Maitituoheti M, Menegaz BA, Krishnan S, Vetter AM, Camacho P, Wu CC, Beird HC, Porter RW, Ingram DR, Ramamoorthy V, Mohiuddin S, McCall D, Truong DD, Cuglievan B, Futreal PA, Velasco AR, Anvar NE, Utama B, Titus M, Lazar AJ, Wang WL, Rodriguez-Aguayo C, Ratan R, Livingston JA, Rai K, MacLeod AR, Daw NC, Hayes-Jordan A, Ludwig JA. The androgen receptor is a therapeutic target in desmoplastic small round cell sarcoma. Nat Commun 13(1):3057, 2022. e-Pub 2022. PMID: 35650195.
- Bhalla AD, Landers SM, Singh AK, Landry JP, Yeagley MG, Myerson GSB, Delgado-Baez CB, Dunnand S, Nguyen T, Ma X, Bolshakov S, Menegaz BA, Lamhamedi-Cherradi SE, Mao X, Song X, Lazar AJ, McCutcheon IE, Slopis JM, Ludwig JA, Lev DC, Rai K, Torres KE. Experimental models of undifferentiated pleomorphic sarcoma and malignant peripheral nerve sheath tumor. Lab Invest 102(6):658-666, 2022. e-Pub 2022. PMID: 35228656.
- Ludwig JA, Van Tine B. Commentary: A Special Edition in bone sarcoma. J Bone Oncol 34:100426, 2022. e-Pub 2022. PMID: 35517059.
- Wu CC, Beird HC, Lamhamedi-Cherradi SE, Soeung M, Ingram D, Truong DD, Porter RW, Krishnan S, Little L, Gumbs C, Zhang J, Titus M, Genovese G, Ludwig JA, Lazar AJ, Hayes-Jordan A, Futreal PA. Multi-site desmoplastic small round cell tumors are genetically related and immune-cold. NPJ Precis Oncol 6(1):21, 2022. e-Pub 2022. PMID: 35379887.
- Truong DD, Lamhamedi-Cherradi SE, Ludwig JA. Targeting the IGF/PI3K/mTOR pathway and AXL/YAP1/TAZ pathways in primary bone cancer. J Bone Oncol 33:100419, 2022. e-Pub 2022. PMID: 35251924.
- Cherradi-Lamhamedi SE, Truong D, Ludwig JA. Understanding sarcoma drug resistance one cell at a time. Cancer Drug Resist 5(1):90-92, 2022. e-Pub 2022. PMID: 35582528.
- Molina ER, Chim LK, Lamhamedi-Cherradi SE, Mohiuddin S, McCall D, Cuglievan B, Krishnan S, Porter RW, Ingram DR, Wang WL, Lazar AJ, Scott DW, Truong DD, Daw NC, Ludwig JA, Mikos AG. Correlation of nuclear pIGF-1R/IGF-1R and YAP/TAZ in a tissue microarray with outcomes in osteosarcoma patients. Oncotarget 13:521-533, 2022. e-Pub 2022. PMID: 35284040.
- Lazcano R, Barreto CM, Salazar R, Carapeto F, Traweek RS, Leung CH, Gite S, Mehta J, Ingram DR, Wani KM, Vu KT, Parra ER, Lu W, Zhou J, Witt RG, Cope B, Thirasastr P, Lin HY, Scally CP, Conley AP, Ratan R, Livingston JA, Zarzour AM, Ludwig J, Araujo D, Ravi V, Patel S, Benjamin R, Wargo J, Wistuba II, Somaiah N, Roland CL, Keung EZ, Solis L, Wang WL, Lazar AJ, Nassif EF. The immune landscape of undifferentiated pleomorphic sarcoma. Front Oncol 12:1008484, 2022. e-Pub 2022. PMID: 36313661.
- Lamhamedi-Cherradi SE, Mohiuddin S, Mishra DK, Krishnan S, Velasco AR, Vetter AM, Pence K, McCall D, Truong DD, Cuglievan B, Menegaz BA, Utama B, Daw NC, Molina ER, Zielinski RJ, Livingston JA, Gorlick R, Mikos AG, Kim MP, Ludwig JA. Transcriptional activators YAP/TAZ and AXL orchestrate dedifferentiation, cell fate, and metastasis in human osteosarcoma. Cancer Gene Ther 28(12):1325-1338, 2021. e-Pub 2021. PMID: 33408328.
- Ludwig JA, Meyers PA, Dirksen U. Ewing's Sarcoma. N Engl J Med 384(15):1476, 2021. e-Pub 2021. PMID: 33852792.
- Parkes A, Wang WL, Patel S, Leung CH, Lin H, Conley AP, Somaiah N, Araujo DM, Zarzour M, Livingston JA, Ludwig J, Roland CL, Ravi V, Benjamin RS, Ratan R. Outcomes of systemic therapy in metastatic phyllodes tumor of the breast. Breast Cancer Res Treat 186(3):871-882, 2021. e-Pub 2021. PMID: 33575859.
- Tarek N, Said R, Andersen CR, Suki TS, Foglesong J, Herzog CE, Tannir NM, Patel S, Ratan R, Ludwig JA, Daw NC. Primary Ewing Sarcoma/Primitive Neuroectodermal Tumor of the Kidney: The MD Anderson Cancer Center Experience. Cancers (Basel) 12(10), 2020. e-Pub 2020. PMID: 33050651.
- Amin HM, Morani AC, Daw NC, Lamhamedi-Cherradi SE, Subbiah V, Menegaz BA, Vishwamitra D, Eskandari G, George B, Benjamin RS, Patel S, Song J, Lazar AJ, Wang WL, Kurzrock R, Pappo A, Anderson PM, Schwartz GK, Araujo D, Cuglievan B, Ratan R, McCall D, Mohiuddin S, Livingston JA, Molina ER, Naing A, Ludwig JA. IGF-1R/mTOR Targeted Therapy for Ewing Sarcoma: A Meta-Analysis of Five IGF-1R-Related Trials Matched to Proteomic and Radiologic Predictive Biomarkers. Cancers (Basel) 12(7), 2020. e-Pub 2020. PMID: 32630797.
- Molina ER, Chim LK, Barrios S, Ludwig JA, Mikos AG. Modeling the Tumor Microenvironment and Pathogenic Signaling in Bone Sarcoma. Tissue Eng Part B Rev 26(3):249-271, 2020. e-Pub 2020. PMID: 32057288.
- Molina ER, Chim LK, Salazar MC, Koons GL, Menegaz BA, Ruiz-Velasco A, Lamhamedi-Cherradi SE, Vetter AM, Satish T, Cuglievan B, Smoak MM, Scott DW, Ludwig JA, Mikos AG. 3D Tissue-Engineered Tumor Model for Ewing's Sarcoma That Incorporates Bone-like ECM and Mineralization. ACS Biomater Sci Eng 6(1):539-552, 2020. e-Pub 2020. PMID: 33463239.
- Parkes A, Urquiola E, Bhosale P, Lin H, Watson K, Wang WL, Feig B, Torres K, Roland CL, Conley AP, Zarzour M, Livingston JA, Ratan R, Ludwig J, Araujo DM, Ravi V, Benjamin RS, Patel S, Somaiah N. PET/CT Imaging as a Diagnostic Tool in Distinguishing Well-Differentiated versus Dedifferentiated Liposarcoma. Sarcoma 2020:8363986, 2020. e-Pub 2020. PMID: 32565716.
- Molina ER, Chim LK, Salazar MC, Mehta SM, Menegaz BA, Lamhamedi-Cherradi SE, Satish T, Mohiuddin S, McCall D, Zaske AM, Cuglievan B, Lazar AJ, Scott DW, Grande-Allen JK, Ludwig JA, Mikos AG. Mechanically tunable coaxial electrospun models of YAP/TAZ mechanoresponse and IGF-1R activation in osteosarcoma. Acta Biomater 100:38-51, 2019. e-Pub 2019. PMID: 31542501.
- Subbiah V, Anderson PM, Kairemo K, Hess K, Huh WW, Ravi V, Daw NC, Somaiah N, Ludwig JA, Benjamin RS, Chawla S, Hong DS, Meric-Bernstam F, Ravizzini G, Kleinerman E, Macapinlac H, Rohren E. Alpha particle Radium 223 dichloride in high-risk osteosarcoma: a phase I dose escalation trial. Clin Cancer Res 25(13):3802-3810, 2019. e-Pub 2019. PMID: 30733229.
- Puerto-Camacho P, Amaral AT, Lamhamedi-Cherradi SE, Menegaz BA, Castillo-Ecija H, Ordóñez JL, Domínguez S, Jordan-Perez C, Diaz-Martin J, Romero-Pérez L, Lopez-Alvarez M, Civantos-Jubera G, Robles-Frías MJ, Biscuola M, Ferrer C, Mora J, Cuglievan B, Schadler K, Seifert O, Kontermann R, Pfizenmaier K, Simón L, Fabre M, ÁM C, Ludwig JA, de Álava E. Preclinical Efficacy of Endoglin-Targeting Antibody-Drug Conjugates for the Treatment of Ewing Sarcoma. Clin Cancer Res 25(7):2228-2240, 2019. e-Pub 2019. PMID: 30420447.
- Subbiah V, Lamhamedi-Cherradi SE, Cuglievan B, Menegaz BA, Camacho P, Huh W, Ramamoorthy V, Anderson PM, Pollock RE, Lev DC, Qiao W, McAleer MF, Benjamin RS, Patel S, Herzog CE, Daw NC, Feig BW, Lazar AJ, Hayes-Jordan A, Ludwig JA. Multimodality Treatment of Desmoplastic Small Round Cell Tumor: Chemotherapy and Complete Cytoreductive Surgery Improve Patient Survival. Clin Cancer Res 24(19):4865-4873, 2018. e-Pub 2018. PMID: 29871905.
- Chim LK, Mikos AG. Biomechanical forces in tissue engineered tumor models. Curr Opin Biomed Eng 6:42-50, 2018. e-Pub 2018. PMID: 30276358.
- Hayes-Jordan AA, Ma X, Menegaz BA, Lamhamedi-Cherradi SE, Kingsley CV, Benson JA, Camacho PE, Ludwig JA, Lockworth CR, Garcia GE, Craig SL. Efficacy of ONC201 in Desmoplastic Small Round Cell Tumor. Neoplasia 20(5):524-532, 2018. e-Pub 2018. PMID: 29626752.
- Hayes-Jordan AA, Coakley BA, Green HL, Xiao L, Fournier KF, Herzog CE, Ludwig JA, McAleer MF, Anderson PM, Huh WW. Desmoplastic Small Round Cell Tumor Treated with Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy: Results of a Phase 2 Trial. Ann Surg Oncol 25(4):872-877, 2018. e-Pub 2018. PMID: 29383611.
- Menegaz BA, Cuglievan B, Benson J, Camacho P, Lamhamedi-Cherradi SE, Leung CH, Warneke CL, Huh W, Subbiah V, Benjamin RS, Patel S, Daw N, Hayes-Jordan A, Ludwig JA. Clinical Activity of Pazopanib in Patients with Advanced Desmoplastic Small Round Cell Tumor. Oncologist 23(3):360-366, 2018. e-Pub 2018. PMID: 29212731.
- Trachtenberg JE, Santoro M, Williams C 3rd, Piard CM, Smith BT, Placone JK, Menegaz BA, Molina ER, Lamhamedi-Cherradi SE, Ludwig JA, Sikavitsas VI, Fisher JP, Mikos AG. Effects of Shear Stress Gradients on Ewing Sarcoma Cells Using 3D Printed Scaffolds and Flow Perfusion. ACS Biomater Sci Eng 4(2):347-356, 2018. e-Pub 2018. PMID: 33418729.
- Wagner MJ, Gopalakrishnan V, Ravi V, Livingston JA, Conley AP, Araujo D, Somaiah N, Zarzour MA, Ratan R, Wang WL, Patel SR, Lazar A, Ludwig JA, Benjamin RS. Vincristine, Ifosfamide, and Doxorubicin for Initial Treatment of Ewing Sarcoma in Adults. Oncologist 22(10):1271-1277, 2017. e-Pub 2017. PMID: 28710342.
- Subbiah V, Meyer C, Zinner R, Meric-Bernstam F, Zahurak ML, O'Connor A, Roszik J, Shaw K, Ludwig JA, Kurzrock R, Azad NA. Phase Ib/II study of safety & efficacy of combination therapy with multikinase VEGF inhibitor Pazopanib and MEK inhibitor Trametinib in advanced soft tissue sarcoma. Clin Cancer Res 23(CCR-17-0272):4027-4034, 2017. e-Pub 2017. PMID: 28377484.
- Ludwig J. Vincristine, Ifosfamide, and Doxorubicin (Vid) for Initial Treatment of Ewing Sarcoma in Adults, 2017. e-Pub 2017.
- Trachtenberg JE, Placone JK, Smith BT, Fisher JP, Mikos AG. Extrusion-based 3D printing of poly(propylene fumarate) scaffolds with hydroxyapatite gradients. J Biomater Sci Polym Ed 28(6):532-554, 2017. e-Pub 2017. PMID: 28125380.
- Santoro M, Menegaz BA, Lamhamedi-Cherradi SE, Molina ER, Wu D, Priebe W, Ludwig JA, Mikos AG. Modeling Stroma-Induced Drug Resistance in a Tissue-Engineered Tumor Model Of Ewing Sarcoma. Tissue Eng Part A 23(1-2):80-89, 2017. e-Pub 2017. PMID: 27923328.
- Higham CS, Steinberg SM, Dombi E, Perry A, Helman LJ, Schuetze SM, Ludwig JA, Staddon A, Milhem MM, Rushing D, Jones RL, Livingston M, Goldman S, Moertel C, Wagner L, Janhofer D, Annunziata CM, Reinke D, Long L, Viskochil D, Baker L, Widemann BC. SARC006: Phase II Trial of Chemotherapy in Sporadic and Neurofibromatosis Type 1 Associated Chemotherapy-Naive Malignant Peripheral Nerve Sheath Tumors. Sarcoma 2017:8685638, 2017. e-Pub 2017. PMID: 29138631.
- Lamhamedi-Cherradi SE, Menegaz BA, Ramamoorthy V, Vishwamitra D, Wang Y, Maywald RL, Buford AS, Fokt I, Skora S, Wang J, Naing A, Lazar AJ, Rohren EM, Daw NC, Subbiah V, Benjamin RS, Ratan R, Priebe W, Mikos AG, Amin HM, Ludwig JA. IGF-1R and mTOR Blockade: Novel Resistance Mechanisms and Synergistic Drug Combinations for Ewing Sarcoma. J Natl Cancer Inst 108(12), 2016. e-Pub 2016. PMID: 27576731.
- Wang Z, Shi N, Naing A, Janku F, Subbiah V, Araujo DM, Patel SR, Ludwig JA, Ramondetta LM, Levenback CF, Ramirez PT, Piha-Paul SA, Hong D, Karp DD, Tsimberidou AM, Meric-Bernstam F, Fu S. Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experience. Cancer Med 5(12):3437-3444, 2016. e-Pub 2016. PMID: 27882721.
- Kesireddy V, Kasper FK. Approaches for building bioactive elements into synthetic scaffolds for bone tissue engineering. J Mater Chem B 4(42):6773-6786, 2016. e-Pub 2016. PMID: 28133536.
- Subbiah V, Hess KR, Khawaja MR, Wagner MJ, Tang C, Naing A, Fu S, Janku F, Piha-Paul S, Tsimberidou AM, Herzog CE, Ludwig JA, Patel S, Ravi V, Benjamin RS, Meric-Bernstam F, Hong DS. Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved Therapies. Sci Rep 6:35448, 2016. e-Pub 2016. PMID: 27748430.
- Jiang Y, Ludwig J, Janku F. Targeted therapies for advanced Ewing sarcoma family of tumors. Cancer Treat Rev 41(5):391-400, 2016. e-Pub 2015. PMID: 25869102.
- Livingston JA, Hess KR, Naing A, Hong DS, Patel S, Benjamin RS, Ludwig JA, Conley A, Herzog CE, Anderson P, Meric-Bernstam F, Kurzrock R, Subbiah V. Validation of prognostic scoring and assessment of clinical benefit for patients with bone sarcomas enrolled in phase I clinical trials. Oncotarget 7(39):64421-64430, 2016. e-Pub 2016. PMID: 27486883.
- Ludwig, J. Flow Perfusion Effects on Three-Dimensional Culture and Drug Sensitivity of Ewring Sarcoma. PNAS 112(33), 2015. e-Pub 2015. PMID: 26240353.
- Ludwig, J. An Oral Formulation of YK-4-279: Preclinical Efficacy and Acquired Resistance Patterns in Ewing’s Sarcoma. Molecular Cancer Therapeutics 10, 2015. e-Pub 2015. PMID: 25964201.
- Pan HY, Morani A, Wang WL, Hess KR, Paulino AC, Ludwig JA, Lin PP, Daw NC, Mahajan A. Prognostic Factors and Patterns of Relapse in Ewing Sarcoma Patients Treated With Chemotherapy and R0 Resection. Int J Radiat Oncol Biol Phys 92(2):349-57, 2015. e-Pub 2015. PMID: 25772182.
- Satelli A, Mitra A, Cutrera JJ, Devarie M, Xia X, Ingram DR, Dibra D, Somaiah N, Torres KE, Ravi V, Ludwig JA, Kleinerman ES, Li S. Universal Marker and Detection Tool for Human Sarcoma Circulating Tumor Cells. Cancer Res 74(6):1645-50, 2014. e-Pub 2014. PMID: 24448245.
- Hayes-Jordan A, Green HL, Lin H, Owusu-Agyemang P, Fitzgerald N, Arunkumar R, Mejia R, Okhuysen-Cawley R, Mauricio R, Fournier K, Ludwig J, Anderson P. Complete Cytoreduction and HIPEC Improves Survival in Desmoplastic Small Round Cell Tumor. Ann Surg Oncol 21(1):220-4, 2014. e-Pub 2014. PMID: 24046124.
- Jiang Y, Subbiah V, Janku F, Ludwig JA, Naing A, Benjamin RS, Brown RE, Anderson P, Kurzrock R. Novel secondary somatic mutations in Ewing's sarcoma and desmoplastic small round cell tumors. PLoS One 9(8):e93676, 2014. e-Pub 2014. PMID: 25119929.
- Fong EL, Lamhamedi-Cherradi SE, Burdett E, Ramamoorthy V, Lazar AJ, Kasper FK, Farach-Carson MC, Vishwamitra D, Demicco EG, Menegaz BA, Amin HM, Mikos AG, Ludwig JA. Modeling Ewing sarcoma tumors in vitro with 3D scaffolds. Proc Natl Acad Sci U S A 110(16):6500-5, 2013. e-Pub 2013. PMID: 23576741.
- Schwartz GK, Tap WD, Qin LX, Livingston MB, Undevia SD, Chmielowski B, Agulnik M, Schuetze SM, Reed DR, Okuno SH, Ludwig JA, Keedy V, Rietschel P, Kraft AS, Adkins D, Van Tine BA, Brockstein B, Yim V, Bitas C, Abdullah A, Antonescu CR, Condy M, Dickson MA, Vasudeva SD, Ho AL, Doyle LA, Chen HX, Maki RG. Cixutumumab and temsirolimus for patients with bone and soft-tissue sarcoma: a multicentre, open-label, phase 2 trial. Lancet Oncol 14(4):371-82, 2013. e-Pub 2013. PMID: 23477833.
- Hayes-Jordan A, Green H, Ludwig J, Anderson P. Toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric patients with sarcomatosis/carcinomatosis: early experience and phase 1 results. Pediatr Blood Cancer 59(2):395-7, 2012. e-Pub 2012. PMID: 22492588.
- Naing A, LoRusso P, Fu S, Hong DS, Anderson P, Benjamin RS, Ludwig J, Chen HX, Doyle LA, Kurzrock R. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res 18(9):2625-31, 2012. e-Pub 2012. PMID: 22465830.
- Wang WL, Katz D, Araujo DM, Ravi V, Ludwig JA, Trent JC, Patel SR, Lin PP, Guadagnolo A, Lòpez-Terrada D, Dei Tos AP, Lewis VO, Lev D, Pollock RE, Zagars GK, Benjamin RS, Madewell JE, Lazar AJ. Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapy. Clin Sarcoma Res 2(1):25, 2012. e-Pub 2012. PMID: 23272660.
- Park MS, Patel SR, Ludwig JA, Trent JC, Conrad CA, Lazar AJ, Wang WL, Boonsirikamchai P, Choi H, Wang X, Benjamin RS, Araujo DM. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer 117(21):4939-47, 2011. e-Pub 2011. PMID: 21480200.
- Ludwig JA, Lamhamedi-Cherradi SE, Lee HY, Naing A, Benjamin R. Dual targeting of the insulin-like growth factor and collateral pathways in cancer: combating drug resistance. Cancers (Basel) 3(3):3029-54, 2011. e-Pub 2011. PMID: 24212944.
- Pandurengan RK, Dumont AG, Araujo DM, Ludwig JA, Ravi V, Patel S, Garber J, Benjamin RS, Strom SS, Trent JC. Survival of patients with multiple primary malignancies: a study of 783 patients with gastrointestinal stromal tumor. Ann Oncol 21(10):2107-11, 2010. e-Pub 2010. PMID: 20348145.
- Vadhan-Raj S, Trent J, Patel S, Zhou X, Johnson MM, Araujo D, Ludwig JA, O'Roark S, Gillenwater AM, Bueso-Ramos C, El-Naggar AK, Benjamin RS. Single-dose palifermin prevents severe oral mucositis during multicycle chemotherapy in patients with cancer: a randomized trial. Ann Intern Med 153(6):358-67, 2010. e-Pub 2010. PMID: 20855800.
- Subbiah V, Ludwig JA. Review: Ewing sarcoma treatment: a role for bisphosphonates?. Clin Adv Hematol Oncol 8(7):503-4, 2010. e-Pub 2010. PMID: 20864919.
- Subbiah V, Madsen VS, Raymond AK, Benjamin RS, Ludwig JA. Of mice and men: divergent risks of teriparatide-induced osteosarcoma. Osteoporos Int 21(6):1041-5, 2010. e-Pub 2010. PMID: 19597911.
- Türk D, Hall MD, Chu BF, Ludwig JA, Fales HM, Gottesman MM, Szakács G. Identification of compunds selectively killing multidrug-resistant cancer cells. Cancer Res 69(21):8293-301, 2009. e-Pub 2009. PMID: 19843850.
- Hall MD, Salam NK, Hellawell JL, Fales HM, Kensler CB, Ludwig JA, Szakács G, Hibbs DE, Gottesman MM. Synthesis, activity and pharmacophore development for isatin-β-thiosemicarbazones with MDR1-selective activity. J Med Chem 52(10):3191-201, 2009. e-Pub 2009. PMID: 19397322.
- Ludwig JA. Personalized therapy of sarcomas: integration of biomarkers for improved diagnosis, prognosis, and therapy selection. Curr Oncol Rep 10(4):329-37, 2008. e-Pub 2008. PMID: 18778559.
- Boersma BJ, Reimers M, Yi M, Ludwig JA, Luke BT, Stephens RM, Yfantis HG, Lee DH, Weinstein JN, Ambs S. A stromal gene signature associated with inflammatory breast cancer. Int J Cancer 122(6):1324-32, 2008. e-Pub 2008. PMID: 17999412.
- Ludwig JA, Szakács G, Martin SE, Chu BF, Cardarelli C, Sauna ZE, Caplen NJ, Fales HM, Ambudkar SV, Weinstein JN, Gottesman MM. Selective toxicity of NSC73306 in MDR1-positive cells as a new strategy to circumvent multidrug resistance in cancer. Cancer Res 66(9):4808-15, 2006. e-Pub 2006. PMID: 16651436.
- Gottesman MM, Ludwig J, Xia D, Szakács G. Defeating drug resistance in cancer. Discov Med 6(31):18-23, 2006. e-Pub 2006. PMID: 17234123.
- Calcagno AM, Ludwig JA, Fostel JM, Gottesman MM, Ambudkar SV. Comparison of drug transporter levels in normal colon, colon cancer, and Caco-2 cells: impact on drug disposition and discovery. Mol Pharm 3(1):87-93, 2006. e-Pub 2006. PMID: 16686373.
Review Articles
- Truong, D, Cardenas Zuniga, R, Ludwig, JA. Desmoplastic Small Round Cell Tumors and the Role of Androgen Receptors. Current treatment options in oncology 26(7):638-647, 2025. e-Pub 2025. PMID: 40536706.
- Loft A, Emont MP, Weinstock A, Divoux A, Ghosh A, Wagner A, Hertzel AV, Maniyadath B, Deplancke B, Liu B, Scheele C, Lumeng C, Ding C, Ma C, Wolfrum C, Strieder-Barboza C, Li C, Truong DD, Bernlohr DA, Stener-Victorin E, Kershaw EE, Yeger-Lotem E, Shamsi F, Hui HX, Camara H, Zhong J, Kalucka J, Ludwig JA, Semon JA, Jalkanen J, Whytock KL, Dumont KD, Sparks LM, Muir LA, Fang L, Massier L, Saraiva LR, Beyer MD, Jeschke MG, Mori MA, Boroni M, Walsh MJ, Patti ME, Lynes MD, Bluher M, Ryden M, Hamda N, Solimini NL, Mejhert N, Gao P, Gupta RK, Murphy R, Pirouzpanah S, Corvera S, Tang S, Das SK, Schmidt SF, Zhang T, Nelson TM, O'Sullivan TE, Efthymiou V, Wang W, Tong Y, Tseng YH, Mandrup S, Rosen ED. Towards a consensus atlas of human and mouse adipose tissue at single-cell resolution. Nat Metab, 2025. e-Pub 2025. PMID: 40360756.
- Ludwig JA. Menin Inhibitors in Pediatric Acute Leukemia: A Comprehensive Review and Recommendations in Collaboration with Adult Leukemia. Leukemia, 2025. e-Pub 2024. PMID: 39179671.
- Cuglievan, B, Kantarjian, HM, Rubnitz, JE, Cooper, T, Zwaan, CM, Pollard, J, DiNardo, C, Kadia, TM, Guest, E, Short, NJ, McCall, DC, Daver, N, Nunez, CA, Haddad, FG, Garcia, MB, Bhalla, K, Maiti, A, Catueno, S, Fiskus, WC, Carter, BZ, Gibson, A, Roth, M, Khazal, SJ, Tewari, P, Abbas, HA, Bourgeois, W, Andreeff, M, Shukla, N, Truong, D, Connors, JS, Ludwig, JA, Stutterheim, J, Salzer, E, Juul-Dam, KL, Sasaki, K, Mahadeo, KM, Tasian, SK, Borthakur, G, Dickson, S, Jain, N, Jabbour, EJ, Meshinchi, S, Garcia-Manero, G, Ravandi, F, Stein, EM, Kolb, EA, Issa, GC. Menin inhibitors in pediatric acute leukemia. Leukemia 38(10):2073-2084, 2024. e-Pub 2024. PMID: 39179671.
- Du Y, Guo JL, Wang J, Mikos AG, Zhang S. Hierarchically designed bone scaffolds: From internal cues to external stimuli. Biomaterials 218:119334, 2019. e-Pub 2019. PMID: 31306826.
- Smoak MM, Pearce HA, Mikos AG. Microfluidic devices for disease modeling in muscle tissue. Biomaterials 198:250-258, 2019. e-Pub 2019. PMID: 30193908.
- Santoro M, Shah SR, Walker JL, Mikos AG. Poly(lactic acid) nanofibrous scaffolds for tissue engineering. Adv Drug Deliv Rev 107:206-212, 2016. e-Pub 2016. PMID: 27125190.
- Kovar H, Amatruda J, Brunet E, Burdach S, Cidre-Aranaz F, de Alava E, Dirksen U, van der Ent W, Grohar P, Grünewald TG, Helman L, Houghton P, Iljin K, Korsching E, Ladanyi M, Lawlor E, Lessnick S, Ludwig J, Meltzer P, Metzler M, Mora J, Moriggl R, Nakamura T, Papamarkou T, Radic Sarikas B, Rédini F, Richter GH, Rossig C, Schadler K, Schäfer BW, Scotlandi K, Sheffield NC, Shelat A, Snaar-Jagalska E, Sorensen P, Stegmaier K, Stewart E, Sweet-Cordero A, Szuhai K, Tirado OM, Tirode F, Toretsky J, Tsafou K, Üren A, Zinovyev A, Delattre O. The second European interdisciplinary Ewing sarcoma research summit--A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget 7(8):8613-24, 2016. e-Pub 2016. PMID: 26802024.
- Lamhamedi-Cherradi SE, Santoro M, Ramammoorthy V, Menegaz BA, Bartholomeusz G, Iles LR, Amin HM, Livingston JA, Mikos AG, Ludwig JA. 3D tissue-engineered model of Ewing's sarcoma. Adv Drug Deliv Rev 79-80C:155-171, 2014. e-Pub 2014. PMID: 25109853.
- Burdett E, Kasper FK, Mikos AG, Ludwig JA. Engineering Tumors: A Tissue Engineering Perspective in Cancer Biology. Tissue Eng Part B Rev 16(3):351-9, 2010. e-Pub 2010. PMID: 20092396.
- Reynoso D, Subbiah V, Trent JC, Guadagnolo BA, Lazar AJ, Benjamin R, Pollock RE, Ludwig JA. Neoadjuvant treatment of soft-tissue sarcoma: a multimodality approach. J Surg Oncol 101(4):327-33, 2010. e-Pub 2010. PMID: 20187067.
- Subbiah V, Anderson P, Lazar AJ, Burdett E, Raymond K, Ludwig JA. Ewing's sarcoma: standard and experimental treatment options. Curr Treat Options Oncol 10(1-2):126-40, 2009. e-Pub 2009. PMID: 19533369.
- Ludwig JA. Ewing sarcoma: historical perspectives, current state-of-the-art, and opportunities for targeted therapy in the future. Curr Opin Oncol 20(4):412-8, 2008. e-Pub 2008. PMID: 18525337.
- Szakács G, Paterson JK, Ludwig JA, Booth-Genthe C, Gottesman MM. Targeting multidrug resistance in cancer. Nat Rev Drug Discov 5(3):219-34, 2006. e-Pub 2006. PMID: 16518375.
- Ludwig JA, Weinstein JN. Biomarkers in cancer staging, prognosis and treatment selection. Nat Rev Cancer 5(11):845-56, 2005. e-Pub 2005. PMID: 16239904.
Abstracts
- Patel RR, Bishop AJ, Lazar AJ, Lin PP, Vaporciyan AA, Benjamin RS, Patel SR, Ludwig JA, Ravi V, Araujo DM. An Institutional Review of Patients Presenting with Localized Primary Intrathoracic Synovial Sarcoma. CIPRIT 2023 Innovations IV in Cancer Prevention and Research Conference, 2023. e-Pub 2023.
- Truong DD, Lamhamedi-Cherradi S, Maitituoheti M, Beird H, Wu C, Krishnan S, Ingram D, McCall D, Cuglievan B, Futreal P, Titus M, Lazar A, Wang W, Rai K, MacLeod A, Ratan R, Livingston J, Daw N, Hayes-Jordan A, Ludwig J. The Epigenetic Impact and Therapeutic Opportunity of AR-Directed Therapy for DSRCT. CTOS 2022 Annual Meeting, 2022. e-Pub 2022.
- Truong DD, Beird H, Wu C, Krishnan S, Ingram D, Lazar A, Keung EZ, Roland CL, Rai K, Yao W, Benjamin R, Somaiah N, Feig BW, Lamhamedi-Cherradi S, Ludwig J. Defining Differentiation States In Well-Differentiated and De-Differentiated Liposarcoma. CTOS 2022 Annual Meeting, 2022. e-Pub 2022.
Book Chapters
- Kumar, R, Ludwig, JA, Madewell, JE. Soft Tissue Sarcomas, 656-669, 2022.
- Ludwig, JA. Ewing Sarcoma Family of Tumors. In: Bone Cancer: Bone Sarcomas & Bone Metastases from Bench to Bedside. 3rd. Elisiever, 605-615, 2022.
- Kumar R, Ludwig JA, Madewell JE. Soft Tissue Sarcoma. In: Oncologic Imaging: A Multidisciplinary Approach. 2nd. Elisiever, 656-669, 2022.
- Ludwig, JA. Ewing's Sarcoma Family of Tumors. In: Bone Cancer: Progression & Therapeutic Approaches, 2nd Edition. Academic Press, 2015.
- Ludwig, JA. Ewing's Sarcoma Family of Tumors. In: Bone Cancer. In: Progression & Therapeutic Approaches. 2nd. Academic Press, 2015.
- Ludwig JA, Burdett E Mikos A. Tumor Engineering: Applications for Cancer Biology and Drug Development. In: Bioengineering. Taylor & Francis Group, 2013.
- Silverman PM, Kumar R, Madewell JE, Ludwig JA, Lewis VO. Oncologic Imaging: A Multidisciplinary Approach. In: A Textbook for Radiologists, Medical Oncologists, and Surgeons. ElSevier, 2012.
- Ludwig JA, Trent J. Targeted Therapy for Sarcoma. In: Current Clinical Oncology:Targeted Cancer Therapy. Humana Pess, 317-334, 2008.
Patents
- Compounds with MDR1-inverse activity. Patent Number: 09711250.2.
- Compounds with MDR1-inverse activity. Patent Number: 2009213153.
- Compounds with MDR1-inverse activity. Patent Number: Patent number not available.
- Compounds with MDR1-inverse activity. Patent Number: WO/2009/102433.
Patient Reviews
CV information above last modified September 01, 2026